Examining the Details of the Recent Updates to MS-DRGs

As we near the end of what some consider the most unprecedented year in coding, there are more updates to review and decipher in preparation for 2021.  

As the science around the COVID-19 pandemic continues to evolve, there remain many unknowns of post-COVID-related conditions. There is an ongoing and urgent need to capture more information about the disease by the global healthcare community.

The Centers for Disease Control and Prevention (CDC), under the National Emergencies Act Section 201 and 301, announced further additions to ICD-10-CM classification related to COVID-19. Additionally, the Centers for Medicare & Medicaid Services (CMS) has posted new guidelines for ICD-10 CM/PCS coding and an updated MS-DRGs, Version 38.1 ─ all effective Jan. 1, 2021. Updates include new ICD-10-CM and PCS codes for COVID-19.

ICD-10 MS-DRGs, Version 38.1 

The ICD-10 MS-DRG grouper software package to accommodate these new codes, Version 38.1, is effective for discharges on or after Jan. 1, 2021.

The six new diagnosis codes proposed are:

  • 82, Pneumonia due to coronavirus disease 2019
  • 81, Multisystem inflammatory syndrome
  • 89, Other specified systemic involvement of connective tissue
  • 52, Encounter for screening for COVID-19
  • 822, Contact with and (suspected) exposure to COVID-19
  • 16, Personal history of COVID-19

The new diagnosis codes were proposed and discussed in detail at the September 2020 ICD-10 Coordination and Maintenance Committee (C&M) meeting. The CDC announcement, along with the new codes and their MS-DRG assignment, is available as a one-page PDF on the CMS website, and the Index and Tabular Addenda for the new codes will be posted on the CDC’s ICD-10 CM page.

COVID-19 Therapeutics and Vaccines

In addition to new ICD-10-PCS codes for the administration of remdesivir and transfusion of convalescent plasma (implemented earlier this year and effective Aug. 1, 2020), the 21 new PCS codes (effective Jan. 1, 2021) include codes to capture the use of additional COVID-19 therapeutics, as well as administration of COVID-19 vaccines.

All of these new PCS codes are classified in table XW0 of the ICD-10-PCS. The codes specify the substance name or type and administration route – whether by subcutaneous/intramuscular injection, IV infusion, or oral administration.

Monoclonal Antibody (10 codes)

Four specific substances classified as monoclonal antibodies – Bamlanivimab, Etesevimab, Leronlimab, and REGN-COV2 – have new PCS codes to track their use in treating COVID-19. Leronlimab is administered by subcutaneous injection, and the other three substances are administered via IV infusion.

  • XW013K6, Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW043E6, Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033E6, Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033F6, Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043F6, Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033G6, Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043G6, Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Three non-specific monoclonal antibody codes were added to allow tracking of other monoclonal antibody drugs approved for the treatment of COVID-19 in the coming months:

  • XW033H6, Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW043H6, Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW013H6, Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

Other Drug Class (5 codes)

Two specific substances – the drug baracitinib (trade name Olumiant®) and an immunomodulator drug known as CD24Fc – also have new codes for tracking their use as COVID-19 therapies. Baracitinib recently received Food and Drug Administration (FDA) emergency use authorization (EUA) as a treatment for COVID-19, in combination with remdesivir. Baracitinib can be administered orally or via gastrostomy/jejunostomy tube. The immunomodulator substance designated CD24Fc is administered via IV infusion.

  • XW0DXM6, Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
  • XW0G7M6, Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6
  • XW0H7M6, Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6
  • XW043L6, Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW033L6, Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Vaccine (6 codes)

Six new PCS codes were added for tracking COVID-19 vaccination while a patient is in the hospital. Likely, the vast majority of vaccines will not be administered to patients while they are in the hospital; nevertheless, these PCS codes will allow for the applicable data to be captured on an inpatient record.

The new PCS codes specify whether the vaccine was a subcutaneous or intramuscular injection, and whether the injection was the first dose or the second, for vaccines that require two injections to complete the therapy. The codes that do not specify dose are to be used for single-dose vaccinations, or when information regarding the dose is not available in the medical record.

  • XW013S6, Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013T6, Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW013U6, Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
  • XW023S6, Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023T6, Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6
  • XW023U6, Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

For MS-DRGs, the new PCS codes are designated Non-OR and will not affect DRG assignment. However, CMS noted in their official announcement, “for hospitalized patients; Medicare pays for the COVID-19 vaccines and their administration separately from the Diagnosis-Related Group rate. As such, Medicare expects that the appropriate CPT codes will be used when a Medicare beneficiary is administered a vaccine while a hospital inpatient.”

 

The CMS announcement, which contains the list of 21 PCS codes, can be accessed on the CMS website here: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software

The Index and Tabular Addenda for the new codes can be found on the CDC’s ICD-10-CM page: https://www.cdc.gov/nchs/icd/icd10cm.htm

Programming Note: Listen to Susan Gatehouse report this story live today during Talk Ten Tuesdays, 10 a.m. EST.

Facebook
Twitter
LinkedIn

Susan Gatehouse, RHIT, CCS,CPC, AHIMA-Approved ICD-10-CM/PCS Trainer

Susan Gatehouse is the founder and chief executive officer of Axea Solutions. An industry expert in revenue cycle management, Gatehouse established Axea Solutions in 1998, and currently partners with healthcare organizations across the nation, to craft solutions for unique challenges in the dynamic world of healthcare reimbursement and data management.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

I022426_SQUARE

Fracture Care Coding: Reduce Denials Through Accurate Coding, Sequencing, and Modifier Use

Expert presenters Kathy Pride, RHIT, CPC, CCS-P, CPMA, and Brandi Russell, RHIA, CCS, COC, CPMA, break down complex fracture care coding rules, walk through correct modifier application (-25, -57, 54, 55), and clarify sequencing for initial and subsequent encounters. Attendees will gain the practical knowledge needed to submit clean claims, ensure compliance, and stay one step ahead of payer audits in 2026.

February 24, 2026
Mastering Principal Diagnosis: Coding Precision, Medical Necessity, and Quality Impact

Mastering Principal Diagnosis: Coding Precision, Medical Necessity, and Quality Impact

Accurately determining the principal diagnosis is critical for compliant billing, appropriate reimbursement, and valid quality reporting — yet it remains one of the most subjective and error-prone areas in inpatient coding. In this expert-led session, Cheryl Ericson, RN, MS, CCDS, CDIP, demystifies the complexities of principal diagnosis assignment, bridging the gap between coding rules and clinical reality. Learn how to strengthen your organization’s coding accuracy, reduce denials, and ensure your documentation supports true medical necessity.

December 3, 2025

Proactive Denial Management: Data-Driven Strategies to Prevent Revenue Loss

Denials continue to delay reimbursement, increase administrative burden, and threaten financial stability across healthcare organizations. This essential webcast tackles the root causes—rising payer scrutiny, fragmented workflows, inconsistent documentation, and underused analytics—and offers proven, data-driven strategies to prevent and overturn denials. Attendees will gain practical tools to strengthen documentation and coding accuracy, engage clinicians effectively, and leverage predictive analytics and AI to identify risks before they impact revenue. Through real-world case examples and actionable guidance, this session empowers coding, CDI, and revenue cycle professionals to shift from reactive appeals to proactive denial prevention and revenue protection.

November 25, 2025
Sepsis: Bridging the Clinical Documentation and Coding Gap to Reduce Denials

Sepsis: Bridging the Clinical Documentation and Coding Gap to Reduce Denials

Sepsis remains one of the most frequently denied and contested diagnoses, creating costly revenue loss and compliance risks. In this webcast, Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, provides practical, real-world strategies to align documentation with coding guidelines, reconcile Sepsis-2 and Sepsis-3 definitions, and apply compliant queries. You’ll learn how to identify and address documentation gaps, strengthen provider engagement, and defend diagnoses against payer scrutiny—equipping you to protect reimbursement, improve SOI/ROM capture, and reduce audit vulnerability in this high-risk area.

September 24, 2025

Trending News

Featured Webcasts

Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue

Stay ahead of the 2026-2027 audit surge with “Top 10 Audit Targets for 2026-2027 for Hospitals & Physicians: Protect Your Revenue,” a high-impact webcast led by Michael Calahan, PA, MBA. This concise session gives hospitals and physicians clear insight into the most likely federal audit targets, such as E/M services, split/shared and critical care, observation and admissions, device credits, and Two-Midnight Rule changes, and shows how to tighten documentation, coding, and internal processes to reduce denials, recoupments, and penalties. Attendees walk away with practical best practices to protect revenue, strengthen compliance, and better prepare their teams for inevitable audits.

January 29, 2026

AI in Claims Auditing: Turning Compliance Risks into Defensible Systems

As AI reshapes healthcare compliance, the risk of biased outputs and opaque decision-making grows. This webcast, led by Frank Cohen, delivers a practical Four-Pillar Governance Framework—Transparency, Accountability, Fairness, and Explainability—to help you govern AI-driven claim auditing with confidence. Learn how to identify and mitigate bias, implement robust human oversight, and document defensible AI review processes that regulators and auditors will accept. Discover concrete remedies, from rotation protocols to uncertainty scoring, and actionable steps to evaluate vendors before contracts are signed. In a regulatory landscape that moves faster than ever, gain the tools to stay compliant, defend your processes, and reduce liability while maintaining operational effectiveness.

January 13, 2026
Surviving Federal Audits for Inpatient Rehab Facility Services

Surviving Federal Audits for Inpatient Rehab Facility Services

Federal auditors are zeroing in on Inpatient Rehabilitation Facility (IRF) and hospital rehab unit services, with OIG and CERT audits leading to millions in penalties—often due to documentation and administrative errors, not quality of care. Join compliance expert Michael Calahan, PA, MBA, to learn the five clinical “pillars” of IRF-PPS admissions, key documentation requirements, and real-life case lessons to help protect your revenue.

November 13, 2025

Trending News

Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more

Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24